Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following conferences in September and October:

• Cantor Global Healthcare Conference: Members of management will be participating in the event on Thursday, September 19, 2024 in New York, NY. They will also be available for one-on-one meetings.

• BofA Healthcare Trailblazers Private Company Conference: Members of management will be participating and available for one-on-one meetings on Wednesday, September 25, 2024 in Boston, MA.

• Cell & Gene Meeting on the Mesa: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a corporate overview on Wednesday, October 9, 2024 at 10:30 a.m. MST in FLW Ballroom F of the Arizona Biltmore Hotel in Phoenix, AZ. Svetlana Lucas, Ph.D., Chief Business Officer, and David Parrot, Chief Financial Officer, will also be available for one-on-one meetings.

About Scribe Therapeutics

Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912409625/en/